RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat lymphoma: targeted drug combo tested in large trial
Disease control OngoingThis study is for people with follicular lymphoma, a type of blood cancer, that has come back or no longer responds to treatment. It tests whether adding the drug tazemetostat to standard therapy (lenalidomide plus rituximab) helps keep the cancer from growing longer than the sta…
Matched conditions: RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE3 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for lymphoma patients: zanubrutinib combo enters phase 3 trial
Disease control OngoingThis phase 3 trial is testing whether a combination of zanubrutinib (a targeted cancer pill) plus an anti-CD20 antibody works better than the current standard of lenalidomide plus rituximab for people with relapsed or refractory follicular or marginal zone lymphoma. About 780 par…
Matched conditions: RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New combo therapy hopes to tackle tough lymphoma
Disease control OngoingThis trial tests two new drug combinations (glofitamab plus atezolizumab or polatuzumab vedotin) in adults with B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The study aims to find the safest dose and see if these combos shrink tumors. About 2…
Matched conditions: RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Immune cell therapy takes on hard-to-treat lymphoma in major trial
Disease control OngoingThis study tests whether a personalized cell therapy (axicabtagene ciloleucel) works better than standard treatments for people with follicular lymphoma that has come back or stopped responding. About 231 adults with this slow-growing blood cancer will receive either the cell the…
Matched conditions: RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE3 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC